Ropes & Gray: Adaptimmune, Galapagos Sign Clinical Collaboration Agreement for Cancer T-Cell Therapy Candidate
June 04, 2024
June 04, 2024
BOSTON, Massachusetts, June 4 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray advised Adaptimmune Therapeutics in a clinical collaboration agreement with Galapagos NV with an option to exclusively license Adaptimmune's next-generation engineered T-cell receptor (TCR) T-cell therapy, called uza-cel, targeting certain head and neck cancer and potential future solid tumor indications using Galapagos' decentralized cell manufacturing platform. The transaction . . .
Ropes & Gray advised Adaptimmune Therapeutics in a clinical collaboration agreement with Galapagos NV with an option to exclusively license Adaptimmune's next-generation engineered T-cell receptor (TCR) T-cell therapy, called uza-cel, targeting certain head and neck cancer and potential future solid tumor indications using Galapagos' decentralized cell manufacturing platform. The transaction . . .